Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831171 | 0.90 | GLA (0.47) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL13495293 | 0.85 | GLA (0.43) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL905300 | 0.84 | GLA (0.57) | GLAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1896218 | 0.84 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL1844624 | 0.84 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL1844621 | 0.84 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL12578570 | 0.84 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL1844620 | 0.84 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL328838 | 0.84 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT | |
| SCHEMBL13579581 | 0.84 | GLA (0.42) | GLAHSD11B1SCN9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929675-B | Adamantane derivatives as focal adhesion kinase inhibitors | 三进制药株式会社 | 2024-02-13 | — | — | CN | disclosed |
| US-11740555-B2 | Resist composition and method for producing resist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-08-29 | — | — | US | disclosed |
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | INCHEON NATIONAL UNIVERSITY RESEARCH & BUSINESS FOUNDATION (KR) | 2023-02-16 | — | — | US | disclosed |
| EP-4074697-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | Samjin Pharmaceutical Co., Ltd. (KR) | 2022-10-19 | — | — | EP | disclosed |
| CN-114929675-A | Novel adamantane derivatives as inhibitors of focal adhesion kinase | 三进制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| WO-2021111311-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | 삼진제약주식회사 | 2021-06-10 | — | — | WO | disclosed |
| WO-2021111311-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | 삼진제약주식회사 | 2021-06-10 | — | — | WO | disclosed |
| US-10358451-B2 | Heterocycles useful as IDO and TDO inhibitors | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-07-23 | — | — | US | disclosed |
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| US-9163012-B2 | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| EP-2276730-A2 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2010141424-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141424-A1 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2009131669-A2 | CARBAMATE AND UREA INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| EP-2064187-A2 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008024497-A2 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | GLA 1611/4885HSD11B1 1/4885SCN9A 999/4885 |
| US-20180127418-A1 | HETEROCYCLES USEFUL AS IDO AND TDO INHIBITORS | IDO1, IDO2, TDO2 | GLA 551/4885HSD11B1 771/4885SCN9A 3547/4885 |
| US-10358451-B2 | Heterocycles useful as IDO and TDO inhibitors | IDO1, IDO2, TDO2 | GLA 551/4885HSD11B1 771/4885SCN9A 3547/4885 |
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | PTK2, DAPK2, DAPK1 | GLA 3283/4885HSD11B1 3564/4885SCN9A 718/4885 |
| US-11740555-B2 | Resist composition and method for producing resist pattern | RER1, GAR1, REV1 | GLA 1218/4885HSD11B1 2634/4885SCN9A 2791/4885 |
| US-20110053943-A1 | CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | GLA 1973/4885HSD11B1 1/4885SCN9A 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.